Fujitsu Prevails in Patent Litigation Against Nanya Technology: related news

Mylan wins generic Prilosec patent litigation

Add our medical news to digg - Mylan wins generic Prilosec patent litigation Add our medical news to NewsVine - Mylan wins generic Prilosec patent litigation Add our medical news to Fark - Mylan wins generic Prilosec patent litigation Add our medical news to Furl - Mylan wins generic Prilosec patent litigation Add our medical news to Shadows - Mylan wins generic Prilosec patent litigation Add our medical news to YahooMyWeb - Mylan wins generic Prilosec patent litigation Add our medical news to Reddit -Mylan wins generic Prilosec patent litigation Add our medical news to StumbleUpon - Mylan wins generic Prilosec patent litigation Add our medical news to Facebook - Mylan wins generic Prilosec patent litigation

Fujitsu Prevails in Patent Litigation Against Nanya Technology

Fujitsu Limited today announced that Nanya Technology Corporation Japan has withdrawn its appeal against a Tokyo District Court ruling which found that Nanya Technology infringes a Fujitsu patent.

NICE Updates on Patent Infringement Litigation Brought Against Verint; Court Reaffirms...

NICE Updates on Patent Infringement Litigation Brought Against Verint; Court Reaffirms Validity of NICE's Patent RA'ANANA, Israel, May 26 /PRNewswire-FirstCall/ -- NICE Systems (NASDAQ: NICE) announced today that in a patent infringement case brought against Verint Americas, Inc. (formerly Witness Systems, Inc.) in the Federal District Court for Northern Georgia in Atlanta, the court found that certain Witness products, which were named in this case, do not infringe NICE's VoIP patent 6871229. NICE intends to appeal this decision. The court rejected Verint's claims challenging the validity of NICE's patent and reaffirmed its validity. The US Patent Office has also, prior to the trial, denied Verint's request for re-examination of the same patent.

Fujitsu Wins DRAM Patent Suit vs Nanya

Fujitsu Ltd announced that Nanya Technology Corp Japan (Nanya Japan) decided May 13, 2008, not to appeal to a higher court the case that Fujitsu had sued Nanya Japan alleging its DRAM patent infringement.

German Court Rules Qualcomm GSM Patent Claim Against Nokia Invalid

The German Federal Patent Court ruled today that Qualcomm’s GSM patent case against Nokia (NYSE: NOK) is invalid, Reuters reports. This is the third court to conclude that the American chipmaker’s patent claims against Nokia are “without merit,” said the Finnish handset maker. The United Kingdom High Court, and the U.S. International Trade Commission have also ruled that Qualcomm’s GSM patent claims against Nokia to be invalid. The two will meet again in German court in October, when a second Qualcomm (NSDQ: QCOM) patent case will be heard. The news comes on the same day that Qualcomm and Nokia are to meet in a Deleware Court over its ongoing patent dispute.

Tellabs Files Patent Suit Against Fujitsu

Tellabs has filed a patent infringement lawsuit against Fujitsu Limited and Fujitsu Network Communications alleging infringement of a recently issued U.S. Patent (No. 7,369,772.). Tellabs asserts that various Fujitsu products are subject to the lawsuit, including reconfigurable optical add/drop multiplexing (ROADM) systems and components that Fujitsu markets within its FLASHWAVE product line.

U.S. Patent on Cytori's Celution System Technology Issued; Celution System Commercialization not Impacted by Recent 6,777,231 Patent Inventorship Decision

SAN DIEGO--(BUSINESS WIRE)--Jun 24, 2008 - U.S. Patent No. 7,390,484 ("the '484 patent") covering Cytori's (NASDAQ:CYTX) Celution(R) System technology was issued today by the United States Patent and Trademark Office. The '484 patent provides Cytori critical market protection for its commercialization of the Celution System in the United States, where the Company is seeking regulatory approval. The '484 patent also protects Cytori's rights to manufacture the Celution Systems in the United States for commercialization into all markets, including Europe and Asia-Pacific, where the device is currently being sold. Other related patent filings are in progress around the globe.

Barr confirms patent challenge of Prevacid SoluTab tablets

Add our medical news to digg - Barr confirms patent challenge of Prevacid SoluTab tablets Add our medical news to NewsVine - Barr confirms patent challenge of Prevacid SoluTab tablets Add our medical news to Fark - Barr confirms patent challenge of Prevacid SoluTab tablets Add our medical news to Furl - Barr confirms patent challenge of Prevacid SoluTab tablets Add our medical news to Shadows - Barr confirms patent challenge of Prevacid SoluTab tablets Add our medical news to YahooMyWeb - Barr confirms patent challenge of Prevacid SoluTab tablets Add our medical news to Reddit -Barr confirms patent challenge of Prevacid SoluTab tablets Add our medical news to StumbleUpon - Barr confirms patent challenge of Prevacid SoluTab tablets Add our medical news to Facebook - Barr confirms patent challenge of Prevacid SoluTab tablets

Barr confirms Entocort patent challenge

Add our medical news to digg - Barr confirms Entocort patent challenge Add our medical news to NewsVine - Barr confirms Entocort patent challenge Add our medical news to Fark - Barr confirms Entocort patent challenge Add our medical news to Furl - Barr confirms Entocort patent challenge Add our medical news to Shadows - Barr confirms Entocort patent challenge Add our medical news to YahooMyWeb - Barr confirms Entocort patent challenge Add our medical news to Reddit -Barr confirms Entocort patent challenge Add our medical news to StumbleUpon - Barr confirms Entocort patent challenge Add our medical news to Facebook - Barr confirms Entocort patent challenge

EntreMed receives new patent for 2-Methoxyestradiol analogs

Add our medical news to digg - EntreMed receives new patent for 2-Methoxyestradiol analogs Add our medical news to NewsVine - EntreMed receives new patent for 2-Methoxyestradiol analogs Add our medical news to Fark - EntreMed receives new patent for 2-Methoxyestradiol analogs Add our medical news to Furl - EntreMed receives new patent for 2-Methoxyestradiol analogs Add our medical news to Shadows - EntreMed receives new patent for 2-Methoxyestradiol analogs Add our medical news to YahooMyWeb - EntreMed receives new patent for 2-Methoxyestradiol analogs Add our medical news to Reddit -EntreMed receives new patent for 2-Methoxyestradiol analogs Add our medical news to StumbleUpon - EntreMed receives new patent for 2-Methoxyestradiol analogs Add our medical news to Facebook - EntreMed receives new patent for 2-Methoxyestradiol analogs

Biopure Corporation wins European patent challenge

Add our medical news to digg - Biopure Corporation wins European patent challenge Add our medical news to NewsVine - Biopure Corporation wins European patent challenge Add our medical news to Fark - Biopure Corporation wins European patent challenge Add our medical news to Furl - Biopure Corporation wins European patent challenge Add our medical news to Shadows - Biopure Corporation wins European patent challenge Add our medical news to YahooMyWeb - Biopure Corporation wins European patent challenge Add our medical news to Reddit -Biopure Corporation wins European patent challenge Add our medical news to StumbleUpon - Biopure Corporation wins European patent challenge Add our medical news to Facebook - Biopure Corporation wins European patent challenge

Composite Technology Announces Issuance of Key Patent

Composite Technology Corporation (CTC) (OTCBB: CPTC) announced today that its CTC Cable Corporation subsidiary has been awarded United States Patent 7,368,162. This patent protects key facets of CTC Cable's ACCC* conductor and core, as well as a wide range of potentially competing designs. The United States Patent and Trademark Office officially granted the patent on May 6, 2008. CTC Cable Corporation now holds six United States patents relating to its ACCC conductor, core and hardware accessories, with additional patent applications pending. CTC Cable Corporation is pursuing corresponding patent applications in many other countries throughout the world.

Composite Technology Announces Issuance of Key Patent

Composite Technology Corporation (CTC) (OTCBB: CPTC) announced today that its CTC Cable Corporation subsidiary has been awarded United States Patent 7,368,162. This patent protects key facets of CTC Cable's ACCC* conductor and core, as well as a wide range of potentially competing designs. The United States Patent and Trademark Office officially granted the patent on May 6, 2008. CTC Cable Corporation now holds six United States patents relating to its ACCC conductor, core and hardware accessories, with additional patent applications pending. CTC Cable Corporation is pursuing corresponding patent applications in many other countries throughout the world.

Composite Technology Announces Issuance of Key Patent

IRVINE, CA--(MARKET WIRE)--May 19, 2008 -- Composite Technology Corporation (CTC) (OTC BB:CPTC.OB - News) announced today that its CTC Cable Corporation subsidiary has been awarded United States Patent 7,368,162. This patent protects key facets of CTC Cable's ACCC* conductor and core, as well as a wide range of potentially competing designs. The United States Patent and Trademark Office officially granted the patent on May 6, 2008. CTC Cable Corporation now holds six United States patents relating to its ACCC conductor, core and hardware accessories, with additional patent applications pending. CTC Cable Corporation is pursuing corresponding patent applications in many other countries throughout the world.

Alnylam Loses Challenge In Europe On Key Patent Covering Gene-Silencing Technology

July 14, 2008 (FinancialWire) Shares of Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) fell after the company said that it lost a challenge in Europe on a key patent which covered certain areas of its gene-silencing technology. Alnylam said claims on the "Glover" patent were overturned by the Opposition Division of the European Patent Office. The patent is licensed from Cancer Research Technology Ltd. and Alnylam said it plans to appeal the decision. Alnylam said that the decision does not alter the position of the company's intellectual property for developing and commercializing RNAi therapeutics, nor does it impact any ongoing business development discussions. The patent is one of 11 held by Alnylam. The goal of gene-silencing, or RNA-based, treatments is to turn off, or silence- the gene at the root of a medical condition, treating the a

Nintendo Loses Patent Suit In East Texas, Of Course

The latest in a long line of patent lawsuits in every patent hoarders favorite district of East Texas involves the game controllers used by Nintendo. A company holds a patent on a 3D controller and sued Nintendo (and Microsoft) for supposedly violating the patent. Not surprisingly, the jury found in favor of the patent holder. Juries quite often side with the patent holder, no matter how questionable the patent may be. In this case, there would seem to be a ton of prior art raising validity questions. The patent itself was filed in November of 2000, at which point there were already numerous game controllers that seem to meet most of the criteria outlined in the claims. Whatever minor differences there may have been between what was on the market and what's in the claims should be seen as an obvious iteration of game controllers.

Broadcom Dodges Patent Lawsuit

Irvine-based Broadcom said late Friday that the U.S. International Trade Commission has rejected a patent infringment suit filed against the firm by SiRF Technology Holdings. According to Broadcom, an ITC administrative law judge issued an Initial Determination Friday, which rejected claims from SiRF Technology Holdings that two of its GPS patents were infringed upon by Global Locate, which Broadcom aquired last July. Global Locate is a developer of GPS and Assisted GPS technology used in cell phones and personal navigation devices. Broadcom has its own lawsuit pending against SiRF, including one which was filed by Global Locate before it was acquired by Broadcom, and subsequent patent infringement suits from Broadcom itself. SiRF had sued Global Locate over their GPS technology in December of 2006.

The Meaningless WiMax Patent Pool

There are some folks who believe that the solution to patent problems is to just have everyone who claims to have a patent on a certain technology throw it into a "patent pool" and then those who use the technology pay up a fee that gets divided up among pool members. It sounds nice, but in practice, it almost never works. Setting up a patent pool actually encourages the wrong behavior: it encourages plenty of other patent holders to claim they deserve to be a part of the pool, and if they're not included, they start suing like crazy. Also, it encourages companies to try to get any kind of patent that might get them included in a pool, leading to all sorts of crazy claims. It's the exact opposite of the type of behavior that should be encouraged.

febit receives U.S. patent for microfluidic extraction method

Add our medical news to digg - febit receives U.S. patent for microfluidic extraction method Add our medical news to NewsVine - febit receives U.S. patent for microfluidic extraction method Add our medical news to Fark - febit receives U.S. patent for microfluidic extraction method Add our medical news to Furl - febit receives U.S. patent for microfluidic extraction method Add our medical news to Shadows - febit receives U.S. patent for microfluidic extraction method Add our medical news to YahooMyWeb - febit receives U.S. patent for microfluidic extraction method Add our medical news to Reddit -febit receives U.S. patent for microfluidic extraction method Add our medical news to StumbleUpon - febit receives U.S. patent for microfluidic extraction method Add our medical news to Facebook - febit receives U.

Drugs industry protecting 'morally unacceptable' patent system

Add our medical news to digg - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to NewsVine - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Fark - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Furl - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Shadows - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to YahooMyWeb - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Reddit -Drugs industry protecting 'morally unacceptable' patent system Add our medical news to StumbleUpon - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Facebook - Drugs industry protecting 'morally unaccep

Supreme Court strengthens patent exhaustion doctrine

The United States Supreme Court has unanimously held in Quanta Computer, Inc. v. LG Electronics, Inc. that the patent law cannot be used to control the subsequent use or disposition of a product "that substantially embodies a patent" once the product has been sold with authority of the patent owner. "The authorized sale of an article that substantially embodies a patent exhausts the patent holder's rights and prevents the patent holder from invoking the patent law to control post-sale use of the article." Patent exhaustion applies whether the patents are directed to products or methods. "Our precedents do not differentiate transactions involving embodiments of patented methods or processes from those involving patented apparatuses or materials.

Silence Therapeutics Announces Successful Opposition of Glover Patent

a leading European RNA interference (RNAi) focused biotechnology company, announced today the successful opposition of a fundamental Alnylam Pharmaceuticals, Inc. European patent resulting in the patent being revoked in its entirety. The Opposition Division of the European Patent Office, following a three day hearing, announced its decision to revoke European Patent EP 1 230 375, exclusively licensed to Alnylam Pharmaceuticals from Cancer Research Technology, Ltd (UK). The Patent, commonly referred to as the "Glover" patent, broadly relates to medicaments comprising an RNA interference mediating RNA molecule. Opposition briefs to the Glover patent had been filed by Silence Therapeutics AG, Sanofi-Aventis Deutschland GmbH, Quark Biotech, Inc.

Environmental Control Corporation Acquires Second Canadian Patent

VANCOUVER, BC -- 05/20/08 -- Environmental Control Corporation ("EVCC") (OTCBB: EVCC) -- It is with great pleasure that Environmental Control Corporation ("EVCC") (OTCBB: EVCC) announces the approval of its second Canadian Patent. The Reverse Flow Catalytic Muffler, Canadian Patent # 2,448,648, now accompanies Canadian Patent # 2,448,742 -- The Combined Catalytic Muffler. Other intellectual property currently held by EVCC includes two U.S. Patents: The Reverse Flow Catalytic Muffler (U.S. Patent # 7,018,590) and The Combined Catalytic Muffler (U.S. Patent # 6,622,482); and one pending patent in Europe: the Reverse Flow Catalytic Muffler (Patent Application # 02742591.7). It is anticipated that the European patent application will be approved and registered in the near future.

Linear Technology receives favorable verdict on patent litigation against Monolithic Power Systems - Quick Facts

Linear Technology Wins Favorable Verdict In Patent Infringement Lawsuit Against Monolithic Power Systems - Update

Verint prevails in patent litigation case against Nice

Nice Systems, a provider of insight from interactions solutions and value-added services, has announced that in a patent infringement case brought against Verint Americas, a provider of actionable intelligence solutions, in the Federal District Court for Northern Georgia in Atlanta, the court found that certain Verint products, which were named in this case, do not infringe Nice's VoIP patent 6871229.

Search took 1.01 seconds.